Search alternatives:
larger decrease » marked decrease (Expand Search)
lower decrease » linear decrease (Expand Search), we decrease (Expand Search), showed decreased (Expand Search)
teer decrease » greater decrease (Expand Search)
Showing 1,981 - 2,000 results of 6,641 for search 'significantly ((((lower decrease) OR (((teer decrease) OR (mean decrease))))) OR (larger decrease))', query time: 0.59s Refine Results
  1. 1981
    Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts.

    Epac activation with 8CPT-AM induced RLC phosphorylation in the perfused hearts. by Yoshiki Ohnuki (576298)

    Published 2025
    Save to List
    Saved in:
  2. 1982
    Epac activation increased RLC phosphorylation via PLC/PKC.

    Epac activation increased RLC phosphorylation via PLC/PKC. by Yoshiki Ohnuki (576298)

    Published 2025
    Save to List
    Saved in:
  3. 1983
    SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort.

    SOSV loads in specimens obtained from bats in the SOSV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Save to List
    Saved in:
  4. 1984
    KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort.

    KASV loads in specimens obtained from bats in the KASV-MARV experimental cohort. by Amy J. Schuh (8520354)

    Published 2025
    Save to List
    Saved in:
  5. 1985
    Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts.

    Pre- and post-study virus-specific IgG responses for bats in the SOSV-MARV and KASV-MARV experimental cohorts. by Amy J. Schuh (8520354)

    Published 2025
    Save to List
    Saved in:
  6. 1986
    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  7. 1987
    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  8. 1988
    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  9. 1989
    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  10. 1990
    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  11. 1991
    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  12. 1992
    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  13. 1993
    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF

    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
    Save to List
    Saved in:
  14. 1994
    Damage characteristics of PU/WG layer.

    Damage characteristics of PU/WG layer. by Hao Yu (157186)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1995
    Joint Efficiency (%) of ABS Polymers at 800 rpm and 1200 rpm.

    Joint Efficiency (%) of ABS Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1996
    Schematic of fixture.

    Schematic of fixture. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1997
    Average shore hardness values of ABS and PC welded samples.

    Average shore hardness values of ABS and PC welded samples. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1998
    Fabricated Fixture with labelled view.

    Fabricated Fixture with labelled view. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1999
    Joint Efficiency (%) of PC Polymers at 800 rpm and 1200 rpm.

    Joint Efficiency (%) of PC Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 2000
    Tensile Strength (MPa) of PC Polymers at 800 rpm and 1200 rpm.

    Tensile Strength (MPa) of PC Polymers at 800 rpm and 1200 rpm. by Shaheer Ahmed Khan (17797647)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: